TKT and glioblastoma: In fact, poor transduction rates (<0.002%) and restricted geometry of vector distribution via the needle track only were the major reasons for failure in the Phase III trials (HSV-TK/GCV treatment with surgical resection and radiation in patients with glioblastoma multiforme) [62].